Skip to contentP
Panacea Life Sciences Holdings, Inc.
P
PLSHPanacea Life Sciences Holdings, Inc. Q2 2021 · 10-Q
Revenue$313.50K$313.50K−94.9% vs Q2 2020 Net Income$27.21K$27.21K−95.8% vs Q2 2020 EPS Diluted$0.00$0.00−100.0% vs Q2 2020 Gross Profit$64,850−98.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Panacea Life Sciences Holdings, Inc. · CIK 1552189 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,144,471N/M Free Cash Flowderived-$1,243,899N/M Margins · derivedGross margin20.7%−31.0 pt vs Q2 2020
Operating margin-459.1%−472.2 pt vs Q2 2020
Net margin8.7%−2.0 pt vs Q2 2020
ended Jun 30, 2021 · filed Aug 23, 2021 · 54 d after period end